CY1106175T1 - Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια - Google Patents

Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια

Info

Publication number
CY1106175T1
CY1106175T1 CY20061101410T CY061101410T CY1106175T1 CY 1106175 T1 CY1106175 T1 CY 1106175T1 CY 20061101410 T CY20061101410 T CY 20061101410T CY 061101410 T CY061101410 T CY 061101410T CY 1106175 T1 CY1106175 T1 CY 1106175T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
acid sequences
isav
sequences
amino acid
Prior art date
Application number
CY20061101410T
Other languages
English (en)
Inventor
Steven Gareth Griffiths
Rachel Jane Ritchie
Joel Heppell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106175(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9918588.6A external-priority patent/GB9918588D0/en
Priority claimed from GB0005848A external-priority patent/GB0005848D0/en
Priority claimed from GB0006674A external-priority patent/GB0006674D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1106175T1 publication Critical patent/CY1106175T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Paper (AREA)
  • Color Image Communication Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει τη χρήση των αλληλουχιών νουκλεϊνικού οξέος ή/και των αλληλουχιών αμινοξέος κατά την προετοιμασία ενός εμβολίου για την προστασία των ψαριών από το μολυσματικό ιό αναιμίας σολομών. Συγκεκριμένα, τέτοια εμβόλια περιέχουν τουλάχιστον μια αλληλουχία νουκλεϊνικού οξέος που προέρχεται από τον ISAV ή τα συνθετικά παρασκευασμένα ανάλογά του, ή τις ουσιαστικά ομόλογες ακολουθίες. Αυτές οι ακολουθίες νουκλεϊνικού οξέος έχουν αντιγραφεί και μεταφραστεί σε ακολουθίες πεπτιδίων που ενσωματώνονται σε μια στρατηγική εμβολιασμού για να προκαλέσουν ανοσία στα αντιγόνα επιφάνειας του ISAV και επομένως στον ίδιο τον ISAV. Επομένως και η χρήση ενός εμβολίου ενάντια στον ISAV, και η ενσωμάτωση των αλληλουχιών πεπτιδίων περιγράφονται στο παρόν κείμενο.
CY20061101410T 1999-08-07 2006-09-28 Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια CY1106175T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9918588.6A GB9918588D0 (en) 1999-08-07 1999-08-07 Sequence
GB0005848A GB0005848D0 (en) 2000-03-11 2000-03-11 Sequence
GB0006674A GB0006674D0 (en) 2000-03-21 2000-03-21 Sequence
PCT/GB2000/002976 WO2001010469A2 (en) 1999-08-07 2000-08-07 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines

Publications (1)

Publication Number Publication Date
CY1106175T1 true CY1106175T1 (el) 2011-06-08

Family

ID=27255591

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101410T CY1106175T1 (el) 1999-08-07 2006-09-28 Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια

Country Status (12)

Country Link
US (7) US6919083B1 (el)
EP (2) EP1200132B2 (el)
AT (1) ATE332712T1 (el)
AU (1) AU6304100A (el)
CA (1) CA2378437C (el)
CY (1) CY1106175T1 (el)
DE (1) DE60029327T2 (el)
DK (2) DK1200132T4 (el)
ES (1) ES2267553T3 (el)
NO (1) NO328740B1 (el)
PT (1) PT1200132E (el)
WO (1) WO2001010469A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60029327T2 (de) 1999-08-07 2007-07-05 Novartis Ag Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DE60017229D1 (de) * 1999-10-18 2005-02-10 Akzo Nobel Nv DNA kodierend für das Strukturalprotein-1 vom infektiösen Lachs Anämie Virus und ihre Verwendungen
CA2402339C (en) * 2000-03-08 2010-01-12 The University Court Of The University Of Aberdeen Viral antigen and vaccine against isav (infectious salmon anaemia virus)
WO2002026784A2 (en) * 2000-09-28 2002-04-04 Akzo Nobel N.V. Matrix proteins m1 and m2 of infections salmon anaemia virus
GB0216414D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2008077413A1 (es) 2006-12-22 2008-07-03 Soluciones Biotecnologicas Innovacion Ltda Vacunas adn en peces
CA2776534A1 (en) 2009-10-02 2011-04-07 The Trustees Of Columbia University In The City Of New York Piscine reovirus diagnostic compositions
SG11201405447QA (en) * 2012-03-09 2014-10-30 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO311648B1 (no) 1999-05-31 2001-12-27 Genomar Asa DNA-sekvenser som kan benyttes til vaksine, forebyggende helsearbeid på fisk og akvatiske organismer og ellers innenbiomedisin, vektor, vaksine mot ILA-virus samt diagnostisk sett
DE60029327T2 (de) 1999-08-07 2007-07-05 Novartis Ag Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DE60017229D1 (de) 1999-10-18 2005-02-10 Akzo Nobel Nv DNA kodierend für das Strukturalprotein-1 vom infektiösen Lachs Anämie Virus und ihre Verwendungen
AU3539401A (en) 2000-01-07 2001-07-16 Akzo Nobel N.V. Vaccine for prevention and/or prophylaxis of infectious salmon anaemia in fish
CA2402339C (en) 2000-03-08 2010-01-12 The University Court Of The University Of Aberdeen Viral antigen and vaccine against isav (infectious salmon anaemia virus)
WO2002026784A2 (en) 2000-09-28 2002-04-04 Akzo Nobel N.V. Matrix proteins m1 and m2 of infections salmon anaemia virus

Also Published As

Publication number Publication date
ATE332712T1 (de) 2006-08-15
ES2267553T3 (es) 2007-03-16
US7128917B2 (en) 2006-10-31
US20100136038A1 (en) 2010-06-03
WO2001010469A3 (en) 2001-09-07
US20070041988A1 (en) 2007-02-22
NO328740B1 (no) 2010-05-03
US7199108B2 (en) 2007-04-03
DK200200167A (da) 2002-04-02
DK177298B1 (en) 2012-10-15
NO20020573L (no) 2002-04-05
EP1200132B2 (en) 2010-02-17
DE60029327T2 (de) 2007-07-05
DE60029327D1 (de) 2006-08-24
PT1200132E (pt) 2006-11-30
EP1637614A2 (en) 2006-03-22
EP1637614A3 (en) 2006-11-29
US20050261227A1 (en) 2005-11-24
US7998484B2 (en) 2011-08-16
CA2378437C (en) 2014-01-21
US6919083B1 (en) 2005-07-19
CA2378437A1 (en) 2001-02-15
AU6304100A (en) 2001-03-05
US7201910B2 (en) 2007-04-10
WO2001010469A2 (en) 2001-02-15
US20050164176A1 (en) 2005-07-28
DK1200132T3 (da) 2006-10-23
US20040146860A1 (en) 2004-07-29
EP1200132A2 (en) 2002-05-02
NO20020573D0 (no) 2002-02-05
DK1200132T4 (da) 2010-04-19
US20120071630A1 (en) 2012-03-22
EP1200132B1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
CY1106175T1 (el) Αλληλουχιες νουκλεϊνικου οξεος και αμινοξεος μολυσματικου ιου αναιμιας σολομων και χρηση τους ως εμβολια
US11559570B2 (en) Prime-boost regimens involving administration of at least one mRNA construct
NO20054608L (no) Influensavirusvaksine
DE602004029657D1 (de) Verbesserte impfstoffe
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DK0661999T3 (da) Vacciner mod felint immundefekt virus (FIV)
ES2327432T3 (es) Vacunas contra el vhc para pacientes con vhc cronica.
HU201682B (en) Process for producing vaccine against malaria
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
ES2644801T3 (es) Antígenos de vacuna quimérica contra el virus de la hepatitis c
DE602004023594D1 (de) Ein virus der infektiösen bronchitis mit veränderten spike-gen
CO5300406A1 (es) Vacuna
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
EP2370100A1 (en) Peptide adjuvants
ATE374622T1 (de) Genetische impstoffe mit adjuvans
CY1107374T1 (el) Εμβολιο ιχθυος εναντι της piscirickettsia salmonis
Wang et al. Augmented humoral and cellular immune responses induced by canine adenovirus type 1 DNA vaccine in BALB/c mice
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
ES2354694T3 (es) Vacunas contra el vhc.
WO2005009372A3 (en) Marek’s disease virus vaccine